Literature DB >> 3363661

Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops.

D BenEzra1, N Matamoros, E Cohen.   

Abstract

Twenty-one children (4 to 12 years old) with severe vernal keratoconjunctivitis refractive to treatment with corticosteroid eyedrops and/or 2% disodium cromoglycate (Optic-rom, Fisons) were treated with CsA 2% eyedrops in oil solution. Eighteen patients (86%) experienced a rapid relief of their subjective symptoms three to four days after initiation of treatment. This was accompanied by objective improvement of ocular manifestations and visual acuity within a week. Sixteen of the children (76%) remained controlled during the 6-week period of treatment. However, only five patients (24%) did not need any additional therapy 2 months after discontinuation of the CsA eyedrops. These findings can be interpreted as an indication for the possible involvement of interleukin secretion in the clinical manifestations of vernal keratoconjunctivitis. Alternatively, the beneficial effects of CsA in this disease may be due to a direct effect on the mast cells preventing the release of their mediators.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3363661

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  10 in total

1.  Modern approach to managing vernal keratoconjunctivitis.

Authors:  Sunil Kumar; Nitin Gupta; Anthony J Vivian
Journal:  Curr Allergy Asthma Rep       Date:  2010-05       Impact factor: 4.806

2.  A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.

Authors:  Yuichi Ohashi; Nobuyuki Ebihara; Hiroshi Fujishima; Atsuki Fukushima; Naoki Kumagai; Yayoi Nakagawa; Kenichi Namba; Shigeki Okamoto; Jun Shoji; Etsuko Takamura; Kunihiko Hayashi
Journal:  J Ocul Pharmacol Ther       Date:  2010-04       Impact factor: 2.671

Review 3.  The role and treatment of inflammation in dry eye disease.

Authors:  Ayse Yagci; Canan Gurdal
Journal:  Int Ophthalmol       Date:  2014-07-26       Impact factor: 2.031

4.  A comparative study between ciclosporine A eye drop (2%) and tacrolimus eye ointment (0.03%) in management of children with refractory vernal keratoconjunctivitis.

Authors:  Mohamed Amin Heikal; Tarek T Soliman; Walid Samir Abousaif; Ahmed Adel Shebl
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-28       Impact factor: 3.117

Review 5.  Ocular allergy guidelines: a practical treatment algorithm.

Authors:  Leonard Bielory
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 6.  Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.

Authors:  Diana Faulds; Karen L Goa; Paul Benfield
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

7.  Short-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study.

Authors:  J W Han; J S Yoon; S Y Jang
Journal:  Eye (Lond)       Date:  2014-08-01       Impact factor: 3.775

Review 8.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 9.  Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.

Authors:  Diane D-S Tang-Liu; Andrew Acheampong
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 5.577

10.  Systemic interventions for severe atopic and vernal keratoconjunctivitis in children and young people up to the age of 16 years.

Authors:  Soyang Ella Kim; Victoria Nowak; Ana Quartilho; Frank Larkin; Melanie Hingorani; Stephen Tuft; Annegret Dahlmann-Noor
Journal:  Cochrane Database Syst Rev       Date:  2020-10-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.